Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737811 | 0.84 | KMT2A (0.41) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL14820518 | 0.75 | MEN1 (0.50) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL18263184 | 0.74 | ALDH1A1 (0.51) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL13736712 | 0.73 | NPC1 (0.46) | KMT2AMAPTLMNACA1CA2 | |
| SCHEMBL9053867 | 0.72 | ALDH1A1 (0.48) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL14806763 | 0.71 | MEN1 (0.46) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL3377745 | 0.71 | MEN1 (0.52) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL11356918 | 0.70 | MEN1 (0.47) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL11626961 | 0.69 | KMT2A (0.53) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL11003199 | 0.69 | KMT2A (0.44) | KMT2AMEN1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | DNPEP, METAP2, ANPEP | KMT2A 362/4885MEN1 1780/4885ALDH1A1 1343/4885 |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, METAP2, ANPEP | KMT2A 362/4885MEN1 1780/4885ALDH1A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.